Chlamydia Increases HIV Acquisition Risk in Women: Mechanism and Prevention

Women with untreated chlamydia (Chlamydia trachomatis) have a 2- to 3-fold increased risk of acquiring HIV from an infected partner compared to women without chlamydia. This synergy drives HIV epidemics in high-prevalence settings.

Biological Mechanisms

• Mucosal barrier disruption: Chlamydia infects columnar epithelial cells → inflammation, ulceration, friability → easier HIV entry
• Immune cell recruitment: Chlamydia ↑ CD4+ T cells, macrophages, dendritic cells (HIV targets) in genital mucosa
• Inflammatory milieu: TNF-α, IL-1β, IL-6, IL-8 → HIV replication enhancement
• Viral shedding: Coinfection ↑ HIV genital shedding in HIV+ partners
• Epithelial integrity loss: Tight junction disruption → paracellular HIV translocation

Epidemiologic Evidence

• Meta-analyses (e.g., McClelland et al., AIDS 2007): Pooled RR 2.0–3.5 for HSV-2, syphilis, chlamydia, gonorrhea, trichomonas, BV
• Chlamydia specifically: High prevalence, often asymptomatic → prolonged exposure window
• Population-attributable fraction: STIs account for substantial proportion of new HIV infections in generalized epidemics

Clinical Implications

• Screen & treat: Annual chlamydia screening for sexually active women <25; older women with risk factors (CDC, USPSTF)
• Expedited partner therapy (EPT): Reduces reinfection
• Integrated services: STI + HIV testing/counseling/PrEP in same visit
• PrEP (pre-exposure prophylaxis): Tenofovir/emtricitabine for high-risk women; STI diagnosis = PrEP indication
• Condom promotion: Dual protection

Public Health Impact

STI control is a structural HIV prevention strategy. Modeling suggests treating curable STIs could avert 10–30% of new HIV infections in high-burden settings. Integration of STI/HIV services is cost-effective.